We are live on ! Find out more
ACP

Acuta Capital Partners Portfolio holdings

AUM $142M
1-Year Est. Return 783.79%
This Fund
S&P 500
This Quarter Est. Return
+9.38%
1 Year Est. Return
+783.79%
3 Year Est. Return
+7,472.18%
5 Year Est. Return
+13,792.16%
10 Year Est. Return
+1,629,663.73%
AUM
$162M
AUM Growth
+$43M
Cap. Flow
+$46.5M
Cap. Flow %
28.77%
Top 10 Hldgs %
56.19%
Holding
71
New
20
Increased
17
Reduced
10
Closed
20

Top Buys

Rank Stock Value
1
AGTC
Applied Genetic Technologies Corporation
AGTC
+$14.3M
2
VCYT icon
Veracyte
VCYT
+$7.86M
3
SPNC
Spectranetics Corp
SPNC
+$6.98M
4
SIOX
Sio Gene Therapies Inc. Common Stock
SIOX
+$3.6M
5
ASND icon
Ascendis Pharma A/S
ASND
+$3.38M

Top Sells

Rank Stock Value
1
CEMP
Cempra, Inc.
CEMP
+$5.49M
2
PTX
Pernix Therapeutics Holdings, Inc.
PTX
+$3.74M
3
INSM icon
Insmed
INSM
+$3.12M
4
FOLD
Amicus Therapeutics
FOLD
+$2.28M
5
CORV
Correvio Pharma Corp. Ordinary Shares (Canada)
CORV
+$2.2M

Sector Composition

Rank Sector Weight
1 Healthcare 81.09%
2 Consumer Discretionary 1.98%
3 Industrials 0.79%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
COLL icon
26
Collegium Pharmaceutical
COLL
$1.15B
$2.32M 1.43%
+130,000
New +$2.25M
LRMR icon
27
Larimar Therapeutics
LRMR
$413M
$1.83M 1.13%
4,408
-3,925
-47% -$1.64M
CDTX
28
DELISTED
Cidara Therapeutics
CDTX
$1.82M 1.13%
+6,500
New +$2M
AUPH icon
29
Aurinia Pharmaceuticals
AUPH
$1.87B
$1.58M 0.98%
524,751
+94,751
+22% +$352K
DCOY
30
Decoy Therapeutics
DCOY
$2.31M
– –
0
– –
CBMX
31
DELISTED
CombiMatrix Corporation
CBMX
$1.42M 0.88%
58,683
– –
EGOV
32
DELISTED
NIC Inc
EGOV
$1.28M 0.79%
70,000
+12,857
+22% +$224K
OTIC
33
DELISTED
Otonomy, Inc.
OTIC
$1.23M 0.76%
53,400
+33,400
+167% +$937K
CUTR
34
DELISTED
Cutera, Inc.
CUTR
$1.16M 0.72%
+75,000
New +$1.07M
HUM icon
35
Humana
HUM
$45B
$1.15M 0.71%
+6,000
New +$1.11M
AGRX
36
DELISTED
Agile Therapeutics
AGRX
$1.1M 0.68%
64
+24
+60% +$512K
CRDC
37
DELISTED
CARDICA INC COM NEW (DE)
CRDC
$923K 0.57%
184,944
+3,000
+2% +$13.4K
OCGN icon
38
Ocugen
OCGN
$424M
$796K 0.49%
2,054
– –
AWAY
39
DELISTED
HOMEAWAY INC COM
AWAY
$778K 0.48%
+25,000
New +$745K
ARAV
40
DELISTED
Aravive, Inc. Common Stock
ARAV
$761K 0.47%
+8,333
New +$844K
SGNT
41
DELISTED
SAGENT PHARMACEUTICALS INC COM STK (DE)
SGNT
$681K 0.42%
+28,000
New +$671K
CEMI
42
DELISTED
Chembio diagnostics, Inc.
CEMI
$638K 0.39%
130,000
-16,099
-11% -$74.4K
ZSAN
43
DELISTED
Zosano Pharma Corporation
ZSAN
$632K 0.39%
125
+94
+303% +$581K
ADAP
44
DELISTED
Adaptimmune Therapeutics
ADAP
$550K 0.34%
+30,000
New +$515K
CEMP
45
DELISTED
Cempra, Inc.
CEMP
$515K 0.32%
15,000
-155,400
-91% -$5.49M
KIN
46
DELISTED
Kindred Biosciences, Inc.
KIN
$341K 0.21%
50,000
-25,000
-33% -$177K
FOMX
47
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$308K 0.19%
+30,000
New +$332K
SMLR
48
DELISTED
Semler Scientific
SMLR
$267K 0.17%
80,935
-34,213
-30% -$121K
MOLG
49
DELISTED
MOL GLOBAL INC SPONSORED ADR
MOLG
$226K 0.14%
147,912
-98,097
-40% -$199K
NUWE icon
50
PUT
Nuwellis
NUWE
$587K
– –
0
– –
1
2
3

Similar funds

EC
EJF Capital Arlington, Virginia $142M AUM 23.3% 1-Year Est. Return
YEPX
Yorktown Energy Partners XI New York $142M AUM 130.51% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
IA
IF Advisors San Antonio, Texas $141M AUM
MAM
Maytree Asset Management Hong Kong $141M AUM 114% 1-Year Est. Return
HA
HFG Advisors Cincinatti, Ohio $142M AUM 16.9% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
KCAM
Kagan Cocozza Asset Management Mickleton, New Jersey $142M AUM 12.02% 1-Year Est. Return

Acuta Capital Partners's Q2 2015 Portfolio in Review

As of Q2 2015, Acuta Capital Partners held 71 positions worth $162M, up 36% from $119M the previous quarter. Its ten largest holdings account for 56% of the portfolio.

Acuta Capital Partners deployed $46.5M of net new capital in Q2 2015, opening 20 new positions and adding to 17 existing holdings. Its largest new stake was Applied Genetic Technologies Corporation: 748,000 shares worth $11.5M.

By sector, the portfolio is most concentrated in Healthcare at 81% of assets, up from 80% a quarter earlier, followed by Consumer Discretionary and Industrials.

On the sell side, the largest reduction was Cempra, Inc., an estimated $5.49M trimmed.

  • Acuta Capital Partners's largest Q2 2015 buy was Applied Genetic Technologies Corporation: 748,000 shares worth $11.5M.
  • Acuta Capital Partners added most to Ascendis Pharma A/S in Q2 2015, an estimated $3.38M increase.
  • Acuta Capital Partners's biggest Q2 2015 reduction was Cempra, Inc., cutting an estimated $5.49M.
  • Acuta Capital Partners fully exited Pernix Therapeutics Holdings, Inc. in Q2 2015, selling an estimated $3.74M.
  • Acuta Capital Partners's ten largest holdings make up 56% of its $162M portfolio in Q2 2015.
  • Acuta Capital Partners opened 20 new positions and closed 20 in Q2 2015.
  • Acuta Capital Partners's portfolio value rose 36% quarter-over-quarter to $162M.

Based on Acuta Capital Partners's 13F filing for Q2 2015, filed 14 Aug 2015.